Yemaachi Furthers African Cancer Research Agenda With New Breast Cancer Mutation, Research Networks

Yemaachi Biotech is preparing to expand a whole-exome sequencing pilot study, while pushing forward several other pan-African cancer research initiatives.
Radiologic patterns of distant organ metastasis in advanced breast cancer patients

Breast cancer (BC) metastases to the abdomen and pelvis affect the liver, mesentery, retroperitoneum, peritoneum, bladder, kidney, ovary, and uterus. The study documented the radiological pattern and features of the chest, bone, abdominal and pelvic (AP) metastases among advanced breast cancer patients.
Yemaachi Presents Findings on Mutation Profiles of Ghanaian Women with Breast Cancer at AORTIC 2023; Announces Formation of African Clinical Cancer Research Network

Results presented in collaboration with Paemka Research Group at the University of Ghana represent largest sequencing study of its kind conducted entirely in Africa to date; Company’s cancer network will advance and scale precision oncology research and collaborations across the continent
African scientists call for research equity as a cancer crisis looms

At Yemaachi, Bediako is developing cancer diagnostics and treatments tailored to Africans, and he describes the limited official data on patients with cancer across Africa as a major challenge.
Assessing the utility of liquid biopsy for detecting actionable genetic mutations among indigenous Ghanaian women with metastatic breast cancer.

Liquid biopsy detected multiple actionable variants in Ghanaian women with breast cancer that a tissue-only workflow missed. cfDNA analysis featured less variations in sample preparation which is a key consideration in resource-limited settings.
Liquid Biopsy – The necessary first step towards democratising precision oncology?African biotech holds the key to transforming not just the health of African people, but our economies as well

While IHC and imaging are useful for diagnosing and staging cancers, they are limited in their ability to inform clinical decision-making regarding the use of increasingly available targeted therapies that are revolutionising cancer care in developed countries. For this, more advanced molecular tests are required, and next generation sequencing-based liquid biopsy tests are at the cutting edge.
Global team to study international differences in COVID-19 immunity

Supported by £3.1 million from the Wellcome Trust, the newly-created WWW Consortium links three leading studies in West Africa (Yemaachi Biotech Heritage Study), the West Indies (Windfall Study in Kingston, Jamaica), and West London (the Legacy Study), each tracking how both the virus and our immunity has evolved against COVID-19.
African biotech holds the key to transforming not just the health of African people, but our economies as well

Why has over a decade of political rhetoric and unprecedented donor support for scientific capacity building not translated into more tangible scientific output?
A closer look reveals a glaring gap in the current structure of the scientific ecosystem in Africa – the almost complete absence of the private sector.
Probing SARS-CoV-2-positive plasma to identify potential factors correlating with mild COVID-19 in Ghana, West Africa

West Africa has recorded a relatively higher proportion of asymptomatic coronavirus disease 2019 (COVID-19) cases than the rest of the world, and West Africa-specific host factors could play a role in this discrepancy. Here, [the authors] assessed the association between COVID-19 severity among Ghanaians with their immune profiles and ABO blood groups.